Using Machine Learning to Predict Final HER2 Status in Invasive Breast Cancer Cases that are Equivocal (2+) by Immunohistochemistry

被引：0
|
作者：
Rasmussen, Sean [1 ,2 ]
Taylor, Valerie [2 ]
Surette, Alexi [3 ]
Barnes, Penny [1 ,2 ]
Bethune, Gillian [1 ,2 ]
机构：
[1] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[2] Dalhousie Univ, Halifax, NS, Canada
[3] Vitalite Hlth Network, Moncton, NB, Canada
来源：
MODERN PATHOLOGY | 2022年 / 35卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
164
引用
收藏
页码：182 / 182
页数：1
相关论文
共 50 条
  • [21] Impact of the 2018 ASCO/CAP HER2 Guideline Updates on HER2 Assessment in Breast Cancer with HER2 Immunohistochemistry Equivocal Results
    Wen, Hannah
    Ventura, Katia
    Xu, Jin
    Ross, Dara
    Dang, Chau
    Robson, Mark
    Norton, Larry
    Morrow, Monica
    Brogi, Edi
    LABORATORY INVESTIGATION, 2019, 99
  • [22] Impact of the 2018 ASCO/CAP HER2 Guideline Updates on HER2 Assessment in Breast Cancer with HER2 Immunohistochemistry Equivocal Results
    Wen, Hannah
    Ventura, Katia
    Xu, Jin
    Ross, Dara
    Dang, Chau
    Robson, Mark
    Norton, Larry
    Morrow, Monica
    Brogi, Edi
    MODERN PATHOLOGY, 2019, 32
  • [23] Impact of the Change of the Criteria for HER2 Immunohistochemistry Interpretation on HER2 Status in Breast Cancer
    Harada, Shuko
    Shen, Dejun
    Wei, Shi
    MODERN PATHOLOGY, 2016, 29 : 44A - 44A
  • [24] Impact of the Change of the Criteria for HER2 Immunohistochemistry Interpretation on HER2 Status in Breast Cancer
    Harada, Shuko
    Shen, Dejun
    Wei, Shi
    LABORATORY INVESTIGATION, 2016, 96 : 44A - 44A
  • [25] Standardized Assessment of the HER2 Status in Breast Cancer by Immunohistochemistry
    Hicks, David G.
    LABMEDICINE, 2011, 42 (08): : 459 - 467
  • [26] HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
    Hou, Yanjun
    Nitta, Hiroaki
    Li, Zaibo
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 147 (01) : 89 - 95
  • [27] Diagnostic value of automated Her2 evaluation in breast cancer: a study on 272 equivocal (score 2+) Her2 immunoreactive cases using an FDA-approved system
    Bragantini, E.
    Morelli, L.
    Cantaloni, C.
    Eccher, C.
    Leonardi, E.
    Cazzolli, D.
    Gasperetti, F.
    Aldovini, D.
    Dalla Palma, P.
    Barbareschi, M.
    VIRCHOWS ARCHIV, 2010, 457 (02) : 176 - 176
  • [28] Assessment of HER2 using the 2018 ASCO/CAP guideline update for invasive breast cancer: a critical look at cases classified as HER2 2+by immunohistochemistry
    Taylor, Valerie J.
    Barnes, Penny J.
    Godwin, Sean C.
    Bethune, Gillian C.
    VIRCHOWS ARCHIV, 2021, 479 (01) : 23 - 31
  • [29] A nomogram to predict HER2 status in breast cancer patients with HER2-borderline disease as determined via immunohistochemistry
    Guo, Qianqian
    Chen, Kai
    Lin, Xiaojie
    Su, Yi
    Xu, Rui
    Dai, Yan
    Qiu, Chang
    Song, Xue
    Mao, Siying
    Chen, Qianjun
    ONCOTARGET, 2017, 8 (55) : 93492 - 93501
  • [30] Change of Her2/neu protein expression level and Her2/neu status in local metastases of breast cancer with its equivocal (2+) expression in primary tumour
    Konyshev, K.
    Kazantseva, N.
    Sazonov, S.
    VIRCHOWS ARCHIV, 2017, 471 : S295 - S296
12345